Viral responses in HCV/HIV-coinfected patients treated with pegIFN α-2a (135 µg/week) plus ribavirin (800 mg/day).

<p>ITT: intention to treat. RVR: rapid virological response. EVR: early virological response. ETR: end of treatment response. SVR: sustained virological response.</p

Adverse events or intercurrent illness throughout treatment with weekly pegIFN-α-2a (135 µg) plus oral Ribavirin (400 mg twice daily); n = 58 patients.

<p>Adverse events or intercurrent illness throughout treatment with weekly pegIFN-α-2a (135 µg) plus oral Ribavirin (400 mg twice daily); n = 58 patients.</p

Factors predictive of rapid (RVR) and sustained virological response (SVR) to anti-hepatitis C virus therapy.

<p>TDF: tenofovir. ABV: abacavir. n.a.: not applicable.</p

Baseline characteristics of the patients included in the study.

<p>M: median. N(t)RTIs: nucleos(t)ide analogue reverse transcriptase inhibitors. NNRTI: nonnucleoside reverse transcriptase inhibitor. PI: protease inhibitor. LDL-C: low-density lipoprotein cholesterol.</p

Percentage of virological responses and relapses as function of rs129679860 genotype (CC vs. CT/TT).

<p>RVR: rapid virological response; EVR: early virological response; ETR: end of treatment response; SVR: sustained virological response.</p

Study flow diagram.

<p>RVR: rapid virological response. EVR: early virological response. ETR: end of treatment response. SVR: sustained virological response. AEs: adverse events.</p

Mean HCV viral decline by IL28B genotype for the standard dose group (SDG) (<b>Figure 2A</b>) and the low-dose group (LDG) (<b>Figure 2B</b>).

<p>Mean HCV viral decline by IL28B genotype for the standard dose group (SDG) (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0048959#pone-0048959-g002" target="_blank"><b>Figure 2A</b></a>) and the low-dose group (LDG) (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0048959#pone-0048959-g002" target="_blank"><b>Figure 2B</b></a>).</p

Mean HCV viral decline between baseline and weeks 1, 2 and 4 for the standard drug dose group (SDG) and the low drug dose group (LDG).

<p>Mean HCV viral decline between baseline and weeks 1, 2 and 4 for the standard drug dose group (SDG) and the low drug dose group (LDG).</p

Baseline Population Characteristics.

<p>Standard drug dose group (SDG); low drug dose group (LDG); human immunodeficiency virus (HIV); highly active antiretroviral treatment (HAART); acquired immunodeficiency syndrome criteria in the past (AIDS); previous intravenous drug user (PIDU); hepatitis C virus (HCV); interleukin 28B (IL28B). ^†Available for 30 patients. ^‡Available for 45 patients.</p

Rapid virological response (RVR) rate by treatment group and IL28B genotype.

<p>Interleukin 28B (IL28B), rapid virological response (RVR), standard drug dose group (SDG), low drug dose group (LDG).</p